Treating asthma with anti-IgE or anti-IL5.
In the last decades, several key mechanisms driving asthma pathophysiooogy have been discovered. These include the role of IgE in allergic disease, and the role of IL-5 in eosinophilic inflammation. In the last few years, tools to block each of these have been developed. At this time, early clinical studies with neutralizing antibodies against both IgE and IL-5 have been performed in asthma patients, with promising results, and larger studies are underway. The mechanisms of, and possible role of, both anti-IgE and anti-IL-5 treatment in asthma are discussed in this review article.
Lötvall
J
J
The Lung Pharmacology Group, Department of Respiratory Medicine and Allergology, Göteborg University, Guldhedsgatan, 10A, 413 46 Gothenburg, Sweden. jan.lotvall@mednet.gu.se
Pullerits
T
T
D000818:Animals; D000906:Antibodies / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D001249:Asthma / Q000628:therapy*; D002986:Clinical Trials as Topic; D004804:Eosinophils / Q000502:physiology; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology*; D015848:Interleukin-5 / Q000276:immunology*; D008407:Mast Cells / Q000502:physiology; D013997:Time Factors
D000906:Antibodies; D000888:Antibodies, Anti-Idiotypic; D015848:Interleukin-5; D007073:Immunoglobulin E